Evotec SE Annual Report: A Performance Summary

I’ve put together this guide to help you understand Evotec SE’s latest performance. Instead of digging through hundreds of pages of dense filings, I’ve broken down the key takeaways so you can decide if this company fits your investment goals.

1. What does this company do?

Think of Evotec as an "R&D engine for hire" for the pharmaceutical industry. Instead of big drug companies doing all their research in-house, they outsource the heavy lifting to Evotec.

They operate through two main segments. Evotec Shared R&D uses AI and massive databases to speed up drug discovery. Just – Evotec Biologics (JEB) uses their "J.POD" platform to manufacture complex drugs. This modular technology is much cheaper to build and run than traditional factories. Together, these services support partners from early research through to clinical manufacturing.

2. Financial performance: The 2025 Snapshot

Evotec is currently transforming to become leaner and more profitable. Here is how they performed compared to 2024:

• Revenue: They brought in €788.4 million, a slight dip of 1.1% from the €797.9 million reported in 2024. This reflects a strategic move away from low-profit legacy contracts.
• Profitability: They are still operating at a loss, but the situation is improving. They reported a net loss of €103.5 million. This is a €92.6 million improvement over the €196.1 million loss in 2024, thanks to better efficiency.
• Operating Health: They reported an adjusted operating profit (EBITDA) of €41.1 million, up €18.6 million from 2024. This shows their day-to-day operations are becoming more efficient.
• Cash Position: As of December 31, 2025, the company held €476.4 million in cash. Proceeds from recent sales provide a runway to fund research without needing to issue more shares, which would reduce your ownership percentage.

3. Major wins and changes: "Project Horizon"

The company is executing "Project Horizon," a plan to simplify operations and focus on high-margin research. A major move this year was the sale of their Toulouse manufacturing site to Sandoz for $350 million.

By selling these expensive factories, they are shifting toward an "asset-light" model. They now focus on licensing technology and providing high-value services rather than owning buildings. This shift aims to improve cash flow and allow the company to focus on its AI-driven drug discovery pipeline.

4. Key risks for investors

• Financial Reporting: Management identified "material weaknesses" in their internal financial controls regarding IT and revenue tracking. They are currently working on remediation, which remains a focus area for the company.
• Customer Concentration: They rely heavily on a few big clients. Their top ten customers provided 61% of total revenue in 2025, up from 52% in 2024. Losing one major partner could cause a significant revenue drop.
• Competition: They face intense pressure from giants like Charles River Laboratories and Wuxi Apptec. Evotec must prove its tech platform is smarter and faster than the competition.
• Talent Attrition: Their value lies in their 3,682 scientific experts. Maintaining this talent base is essential for their ongoing ability to innovate.

5. The Bottom Line

Evotec is a "picks and shovels" play in the biotech world. They are betting that selling heavy assets and focusing on high-margin research will make them more profitable. While they narrowed their losses this year, the combination of weak financial reporting controls and heavy reliance on a few big customers makes this a "wait and see" situation. Watch the next two quarterly reports to see if their cost savings lead to actual profit and if they successfully resolve their financial reporting issues.